Cogent Biosciences Inc

NASDAQ COGT

Data sourced from

and

Download Data

Cogent Biosciences Inc Short-Term Debt to Total Assets Ratio 5 year CAGR for the quarter ending March 31, 2024: -30.49%

Cogent Biosciences Inc Short-Term Debt to Total Assets Ratio 5 year CAGR is -30.49% for the quarter ending March 31, 2024. The short-term debt to total assets ratio measures the proportion of short-term debt to total assets of a company. It is calculated by dividing the short-term debt by the total assets. This ratio indicates the extent to which short-term debt contributes to the company's total asset structure. A higher ratio suggests a higher level of short-term debt relative to total assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Cogent Biosciences Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2023 was 0.00, a -68.92% change year over year.
Cogent Biosciences Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2022 was 0.01, a 29.94% change year over year.
Cogent Biosciences Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2021 was 0.01, a -79.08% change year over year.
Cogent Biosciences Inc Short-Term Debt to Total Assets Ratio for the quarter ending March 31, 2020 was 0.04, a 129.65% change year over year.

NASDAQ: COGT

Cogent Biosciences Inc

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive, Cambridge, MA, United States, 02140
Employees	164
Sector	Healthcare
Industry	Biotechnology

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Key trends